Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer.
Repository Usage Stats
Since androgen receptor (AR) signaling is critically required for the development of prostate cancer (PCa), targeting AR axis has been the standard treatment of choice for advanced and metastatic PCa. Unfortunately, although the tumor initially responds to the therapy, treatment resistance eventually develops and the disease will progress. It is therefore imperative to identify the mechanisms of therapeutic resistance and novel molecular targets that are independent of AR signaling. Recent advances in pathology, molecular biology, genetics and genomics research have revealed novel AR-independent pathways that contribute to PCa carcinogenesis and progression. They include neuroendocrine differentiation, cell metabolism, DNA damage repair pathways and immune-mediated mechanisms. The development of novel agents targeting the non-AR mechanisms holds great promise to treat PCa that does not respond to AR-targeted therapies.
DNA damage repair
Published Version (Please cite this version)10.1016/j.ajur.2018.11.002
Publication InfoHu, Hailiang; Huang, Jiaoti; Xu, Lingfan; Chen, Junyi; Liu, Weipeng; & Liang, Chaozhao (2019). Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer. Asian journal of urology, 6(1). pp. 91-98. 10.1016/j.ajur.2018.11.002. Retrieved from https://hdl.handle.net/10161/18631.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Assistant Professor of Pathology
Endowed Department Chair of Pathology
I am a physician-scientist with clinical expertise in the pathologic diagnosis of genitourinary tumors including tumors of the prostate, bladder, kidney and testis. Another area of interest is gynecologic tumors. In my research laboratory we study prostate cancer, focusing on molecular mechanisms of carcinogenesis and tumor progression, as well as biomarkers, imaging and novel therapeutic strategies. In addition to patient care and research, I am also passionate about education. I have trained n
Alphabetical list of authors with Scholars@Duke profiles.